The North America intravenous solutions market size was estimated at USD 5.61 billion in 2025 and is projected to reach USD 11.18 billion by 2033, growing at a CAGR of 9.2% from 2026 to 2033. The rising prevalence of chronic diseases, the increasing demand for parenteral nutrition and critical care support, and the presence of advanced healthcare infrastructure, coupled with high surgical volumes across North America.
These factors collectively drive the demand for intravenous solutions across hospitals, intensive care units, and infusion centers. The rising burden of chronic diseases including cancer, chronic kidney disease, and gastrointestinal disorders continues to expand the patient pool requiring long-term intravenous therapy for hydration, drug delivery, and nutritional support. According to the Centers for Disease Control and Prevention published study in 2025, 6 in 10 adults in the U.S. have at least one chronic disease, and 4 in 10 have two or more. This highlights a significant demand for ongoing clinical management. In addition, the American Cancer Society estimates over 2 million new cancer cases annually in the U.S. in 2025, many requiring IV solutions for chemotherapy and supportive care, which drives the need for IV fluid and electrolyte management.
Moreover, the increasing demand for parenteral nutrition and critical care support significantly drives the market, especially in intensive care units (ICUs), neonatal care, and post-surgical settings. A growing number of critically ill and malnourished patients require intravenous nutritional support when oral or enteral feeding is not possible. This is particularly true in cases of severe illness, trauma, premature births, and complex surgical recoveries. Therapies such as total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) have become essential in patient management, boosting the demand for IV solutions in acute and critical care environments.
In addition, advanced healthcare infrastructure and high surgical volumes in North America contribute significantly to market growth. The region has a well-established network of hospitals, ambulatory surgical centers, and specialized care facilities that routinely use intravenous therapies for many medical procedures. Surgical interventions, from routine to complex, require consistent administration of IV fluids for perioperative stabilization and post-operative recovery. The strong presence of skilled healthcare professionals and broad access to advanced treatment technologies ensure the continued efficient use of IV solutions across clinical settings.
Furthermore, the increasing demand for intravenous fluids is further driven by rising hospital admissions and critical care needs. The growing burden on healthcare systems, especially in acute and emergency care, has intensified the need for a consistent, reliable supply of IV solutions. For instance, in January 2025, Baxter International Inc. increased allocations of two sodium chloride IV solutions to 100% to improve product availability across the U.S. healthcare system. However, the company reported a 1-2-week distribution lag, with some hospitals experiencing delays of 2-3 weeks due to ongoing supply chain constraints. This shows how rising clinical demand is pushing manufacturers to enhance production capacity and streamline distribution networks to ensure uninterrupted supply.
This product will be delivered within 1-3 business days.
These factors collectively drive the demand for intravenous solutions across hospitals, intensive care units, and infusion centers. The rising burden of chronic diseases including cancer, chronic kidney disease, and gastrointestinal disorders continues to expand the patient pool requiring long-term intravenous therapy for hydration, drug delivery, and nutritional support. According to the Centers for Disease Control and Prevention published study in 2025, 6 in 10 adults in the U.S. have at least one chronic disease, and 4 in 10 have two or more. This highlights a significant demand for ongoing clinical management. In addition, the American Cancer Society estimates over 2 million new cancer cases annually in the U.S. in 2025, many requiring IV solutions for chemotherapy and supportive care, which drives the need for IV fluid and electrolyte management.
Moreover, the increasing demand for parenteral nutrition and critical care support significantly drives the market, especially in intensive care units (ICUs), neonatal care, and post-surgical settings. A growing number of critically ill and malnourished patients require intravenous nutritional support when oral or enteral feeding is not possible. This is particularly true in cases of severe illness, trauma, premature births, and complex surgical recoveries. Therapies such as total parenteral nutrition (TPN) and peripheral parenteral nutrition (PPN) have become essential in patient management, boosting the demand for IV solutions in acute and critical care environments.
In addition, advanced healthcare infrastructure and high surgical volumes in North America contribute significantly to market growth. The region has a well-established network of hospitals, ambulatory surgical centers, and specialized care facilities that routinely use intravenous therapies for many medical procedures. Surgical interventions, from routine to complex, require consistent administration of IV fluids for perioperative stabilization and post-operative recovery. The strong presence of skilled healthcare professionals and broad access to advanced treatment technologies ensure the continued efficient use of IV solutions across clinical settings.
Furthermore, the increasing demand for intravenous fluids is further driven by rising hospital admissions and critical care needs. The growing burden on healthcare systems, especially in acute and emergency care, has intensified the need for a consistent, reliable supply of IV solutions. For instance, in January 2025, Baxter International Inc. increased allocations of two sodium chloride IV solutions to 100% to improve product availability across the U.S. healthcare system. However, the company reported a 1-2-week distribution lag, with some hospitals experiencing delays of 2-3 weeks due to ongoing supply chain constraints. This shows how rising clinical demand is pushing manufacturers to enhance production capacity and streamline distribution networks to ensure uninterrupted supply.
North America Intravenous Solutions Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the North America intravenous solutions market report based on type, nutrients, end use and regions:Type Outlook (Revenue, USD Million, 2021-2033)
- Total Parenteral Nutrition Market (TPN)
- Peripheral Parenteral Nutrition (PPN)
Nutrients Outlook (Revenue, USD Million, 2021-2033)
- Carbohydrates
- Single dose amino acid solution
- Vitamins & Minerals (Salt and electrolyte)
- Parenteral lipid emulsion
- Others
End Use Outlook (Revenue, USD Million, 2021-2033)
- Hospitals
- Infusion Centers
- Home Healthcare
Country Outlook (Revenue, USD Million, 2021-2033)
- U.S.
- Canada
- Mexico
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Market Variables, Trends, & Scope
Chapter 4. North America Intravenous Solutions Market: Type Estimates & Trend Analysis
Chapter 5. North America Intravenous Solutions Market: Nutrients Estimates & Trend Analysis
Chapter 6. North America Intravenous Solutions Market: End Use Estimates & Trend Analysis
Chapter 7. North America Intravenous Solutions Market: Country Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Baxter
- Fresenius Kabi AG
- B. Braun Medical Inc.
- ICU Medical, Inc.
- Pfizer Inc.
- Otsuka Pharmaceutical Co., Ltd.
- Grifols, S.A.
- JW Life Science
- CSLVifor (formerly Vifor Pharma)
- BD (Becton, Dickinson and Company)
- Terumo Corporation
- Amphastar Pharmaceuticals, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 120 |
| Published | May 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 5.61 Billion |
| Forecasted Market Value ( USD | $ 11.18 Billion |
| Compound Annual Growth Rate | 9.2% |
| Regions Covered | North America |
| No. of Companies Mentioned | 12 |
